about
Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for womenAutotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic reviewSerum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic reviewPharmacological inhibition of mTORC1 prevents over-activation of the primordial follicle pool in response to elevated PI3K signalingCisplatin Induces Overactivation of the Dormant Primordial Follicle through PTEN/AKT/FOXO3a Pathway which Leads to Loss of Ovarian Reserve in MiceAMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapyStem cells' guided gene therapy of cancer: New frontier in personalized and targeted therapy.Melatonin and Fertoprotective Adjuvants: Prevention against Premature Ovarian Failure during Chemotherapy.Preserving fertility in patients undergoing treatment for breast cancer: current perspectives.Detection of non-Hodgkin's lymphoma in ovarian cortex pieces during the process of cryopreservation.A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer.Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing folliclesFACS-sorted putative oogonial stem cells from the ovary are neither DDX4-positive nor germ cells.Lentivirus-mediated bcl-2 gene therapy improves function and structure of chemotherapy-damaged ovaries in wistar rats.Fertility preservation in women with cancer.Hyaluronic acid prevents immunosuppressive drug-induced ovarian damage via up-regulating PGRMC1 expression.Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatinEradication of Human Ovarian Cancer Cells by Transgenic Expression of Recombinant DNASE1, DNASE1L3, DNASE2, and DFFB Controlled by EGFR Promoter: Novel Strategy for Targeted Therapy of Cancer.Initiation of puberty in mice following decellularized ovary transplant.Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovaryScreening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.Human umbilical cord mesenchymal stem cell transplantation restores damaged ovariesLong-Term Follow-Up of Chemotherapy-Induced Ovarian Failure in Young Breast Cancer Patients: The Role of Vascular ToxicityFollicular growth after xenotransplantation of cryopreserved/thawed human ovarian tissue in SCID mice: dynamics and molecular aspectsEtoposide damages female germ cells in the developing ovary.Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.Tamoxifen prevents apoptosis and follicle loss from cyclophosphamide in cultured rat ovaries.Challenges and Potential for Ovarian Preservation with SERMs.In vitro follicle growth supports human oocyte meiotic maturation.Intraovarian transplantation of primordial follicles fails to rescue chemotherapy injured ovariesGoserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover.Fertility counseling of young breast cancer patients.Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.Multidrug-resistant transport activity protects oocytes from chemotherapeutic agents and changes during oocyte maturationLongitudinal observation of serum anti-Müllerian hormone in three girls after cancer treatment.Irinotecan metabolite SN38 results in germ cell loss in the testis but not in the ovary of prepubertal mice.Re-implantation of cryopreserved ovarian cortex resulting in restoration of ovarian function, natural conception and successful pregnancy after haematopoietic stem cell transplantation for Wilms tumour.Safety considerations for transplanting cryopreserved ovarian tissue to restore fertility in female patients who have recovered from Ewing's sarcoma.Sexual and fertility adverse effects associated with chemotherapy treatment in women.
P2860
Q26771979-121356F4-7B78-404A-8FD5-4BB0BD33E28FQ26864087-8B038712-D917-44EC-A14C-23589B05B632Q28384104-A28D16B9-6F82-4D74-AE9D-C76CBCC9D66FQ28484974-EBBA5F0F-A3B6-41EA-B221-98B49375DB85Q28551950-105DACE0-CF43-40D4-BDC8-9B722516EA2BQ30353654-BC536815-EFBF-4F9E-B873-2D252151E19CQ33653485-B75DFE91-B735-407F-8CE4-00545E7A2E1AQ33838766-2C2CA86A-51A9-4FEA-9185-8AC514EB99FCQ33939688-342A5B55-3923-44E9-BC78-E77A8847DD70Q34145742-55F68519-5FC7-4554-B360-63BF699C3ED5Q34199333-023B7F65-725E-4934-8BCC-E3C2801F0BDFQ34230276-5D72C418-4BC1-4A3D-97E4-7CC5CC72852EQ34530882-6F07FFAB-FA5A-40F4-BEF8-5073BFE541DBQ34545919-ED5C2CD2-BB3F-4D8F-A7E5-D47A6F13676BQ34729392-15BAE083-B6CB-4DDC-B796-DE291714DBC8Q34830224-94D51200-999F-413B-BB06-8F49A6C69040Q34905992-E6511E62-B3CA-4FA4-A4F2-FDDF91AA3FDAQ35109273-20DA8844-C2D5-482D-8139-65D8C4F48C88Q35148516-0DC5F6C3-C518-454C-97EC-8B77E7013F9AQ35201332-B01A1E2F-4E01-4382-9A5E-356F49779E13Q35815806-058A88CA-6206-42D7-98E0-62D511EFEA21Q36057466-FA1FC602-5F5E-4C80-AC71-2D53E3FD6F5AQ36064942-627B6FB2-DB87-403F-8693-30F8DCEB67DEQ36087872-A5083B98-4B59-4C4D-BCED-17ECBF5C03C9Q36100739-1D065E64-1AC7-4603-904B-ABD60B1753BAQ36261447-A2FB077A-DAF6-42F6-8E50-79FC8F754938Q36282791-488D1B52-B2AD-4BC5-AA3B-15A8A4FA06D4Q36282795-3E1BDFE7-5CDA-4DEE-A25C-8D273B9362D1Q36323613-E178CBBA-07BF-4634-AD0A-51A31365C491Q36660959-DDCC1A93-D416-4FC7-AD20-331E9D57FDA7Q36661462-A4F52D97-B088-4B60-AF86-A5A0A120CDF8Q36963384-72A15BD1-AB5B-48C3-B1F4-C5C018880F9DQ37249356-6C4E80B4-7B3E-4C40-AA97-3813158DC6B3Q37253591-F5243028-8F4B-4D3E-A9E5-5EE942C8ABC6Q37281939-7593C75E-6ED4-47AB-9637-8C87140C18DCQ37348851-71D653CF-6819-48FF-97E8-C4CAEC44E8FEQ37400331-C8CDC46F-633D-4A7D-A11F-B740F655EC25Q37519135-9A84F201-EDF3-468B-8268-F333B79E6229Q38184581-ED3C7B10-BFFF-46FA-A96E-2CF2D087A5CDQ38208378-09A0F40D-AAAF-44B0-9541-0BAC88E31B1E
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
How do chemotherapeutic agents damage the ovary?
@ast
How do chemotherapeutic agents damage the ovary?
@en
How do chemotherapeutic agents damage the ovary?
@nl
type
label
How do chemotherapeutic agents damage the ovary?
@ast
How do chemotherapeutic agents damage the ovary?
@en
How do chemotherapeutic agents damage the ovary?
@nl
prefLabel
How do chemotherapeutic agents damage the ovary?
@ast
How do chemotherapeutic agents damage the ovary?
@en
How do chemotherapeutic agents damage the ovary?
@nl
P2093
P2860
P3181
P356
P1476
How do chemotherapeutic agents damage the ovary?
@en
P2093
P2860
P304
P3181
P356
10.1093/HUMUPD/DMS022
P407
P577
2012-01-01T00:00:00Z